For biotech investors, healthcare professionals, and medical researchers — this New to The Street interview from the New York Stock Exchange features David P. Luci, CEO of Acurx Pharmaceuticals (NASDAQ: ACXP), discussing groundbreaking new data published in Nature magazine that validates the company’s novel Pol III inhibitor antibiotic class.
The results, from a public-private partnership with Leiden University Medical Center in the Netherlands, show that Acurx’s antibiotics are microbiome-sparing — effectively killing harmful bacteria like C. difficile, MRSA, anthrax, and VRE while preserving healthy gut flora. This innovation could mark a major shift in infectious disease treatment, addressing one of medicine’s toughest challenges: curing infection without damaging the microbiome.
Luci shares updates on the upcoming Phase 3 clinical trial for C. difficile infections — a condition that causes 29,000 deaths and 500,000 cases annually in the U.S. He also details new government-sponsored studies, collaborations with University of Houston, and the company’s plans for additional antibiotics targeting drug-resistant pathogens.
With 96% cure rates and zero reinfections in prior trials, Acurx is positioned to redefine how antibiotic therapies are developed and delivered — potentially ending a 30-year drought in new antibiotic innovation.